Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Rating Upgraded by Zacks Research

Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Monday, December 29th. Citigroup raised their price objective on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday. Oppenheimer reiterated an “outperform” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, November 7th. Finally, Wall Street Zen raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Two investment analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $34.00.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX traded down $0.44 during midday trading on Tuesday, reaching $24.25. The company’s stock had a trading volume of 663,856 shares, compared to its average volume of 1,273,300. The stock has a market capitalization of $2.96 billion, a P/E ratio of 14.35, a PEG ratio of 0.71 and a beta of 0.75. The firm has a 50 day moving average price of $23.86 and a 200-day moving average price of $22.30. Catalyst Pharmaceuticals has a 12-month low of $19.05 and a 12-month high of $26.58.

Insider Activity

In related news, Director Molly Harper sold 26,746 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $23.25, for a total transaction of $621,844.50. Following the completion of the transaction, the director owned 2,360 shares of the company’s stock, valued at approximately $54,870. The trade was a 91.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Parkside Financial Bank & Trust grew its holdings in shares of Catalyst Pharmaceuticals by 17.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 469 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in Catalyst Pharmaceuticals by 1.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 472 shares in the last quarter. Jones Financial Companies Lllp grew its stake in Catalyst Pharmaceuticals by 14.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock worth $79,000 after buying an additional 498 shares in the last quarter. Lifestyle Asset Management Inc. raised its position in shares of Catalyst Pharmaceuticals by 3.4% during the 4th quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock valued at $393,000 after buying an additional 553 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its position in shares of Catalyst Pharmaceuticals by 55.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 630 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).